Dr. Javed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
Chicago, IL 60637Phone+1 888-824-0200Fax+1 773-702-9060
Education & Training
Yale-New Haven Medical CenterResidency, Neurology, 2001 - 2004
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2000 - 2003
Southern Illinois University School of MedicineClass of 2000
Certifications & Licensure
IL State Medical License 2003 - 2026
IN State Medical License 2011 - 2015
CT State Medical License 2003 - 2004- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis Start of enrollment: 2011 Jun 01
- Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses Start of enrollment: 2016 Dec 20
Publications & Presentations
PubMed
- T1 mapping from routine 3D T1-weighted inversion recovery sequences in clinical practice: comparison against reference inversion recovery fast field echo T1 scans and ...Griffin Young, Vivian S Nguyen, Quentin Howlett-Prieto, Amanda Frisosky Abuaf, Timothy J Carroll
Neuroradiology. 2024-10-01 - 1 citationsEffectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center ...Laura Dresser, Widad Abou Chaar, Anthony T Reder, Amanda Frisosky Abuaf, Veronica P Cipriani
Multiple Sclerosis and Related Disorders. 2023-06-01 - 3 citationsEffectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study.Amanda Frisosky Abuaf, Adil Javed, Samuel R Bunting, Timothy J Carroll, Anthony T Reder
Multiple Sclerosis and Related Disorders. 2023-03-01
Press Mentions
203 UChicago Medicine Doctors Named to 2022 Top Docs ListJanuary 21st, 2022- New UPLIZNA® (Inebilizumab-Cdon) Data in People with Neuromyelitis Optica Spectrum Disorder (NMOSD) to Be Presented at the American Academy of Neurology’s 73rd Annual MeetingApril 5th, 2021
New Multiple Sclerosis Treatment Offers Breakthrough for PatientsApril 20th, 2017- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
